On the 28th morning, Peptron shares were strong. The news came that Eli Lilly and Company, the world's No. 1 drugmaker by market capitalization, will establish a production base in Korea for the obesity treatment "Mounjaro."
As of 9:57 a.m. that day, Peptron was trading at 359,000 won on the KOSDAQ market, up 51,000 won (16.56%) from the previous session.
As it became known that Eli Lilly and Company is pushing a plan to build an integrated production system for Mounjaro in the North Chungcheong area, Peptron is being mentioned as Eli Lilly and Company's finished goods production partner. Peptron holds long-acting peptide injectable technology required for obesity treatments.
Meanwhile, Eli Lilly and Company has been conducting joint research with Peptron since Oct. last year to evaluate the long-acting drug delivery technology "SmartDepot," held by Peptron.